Literature DB >> 17357380

Aminotransferase activities in healthy subjects receiving three-day dosing of 4, 6, or 8 grams per day of acetaminophen.

Anthony R Temple1, Joseph M Lynch, Jason Vena, Joanna F Auiler, Cathy K Gelotte.   

Abstract

INTRODUCTION: This multiple-dose pharmacokinetic study has a randomized, double-blind, placebo-controlled, parallel-group design with three dosing regimens. Healthy subjects received repeated doses of acetaminophen (4 then 6 g/d or 4 then 8 g/d) or placebo.
METHODS: The disposition of acetaminophen and its metabolites and the tolerability of increased acetaminophen doses over 3 days of continuous consumption were characterized. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities measured throughout the study were consistent across the acetaminophen 4, 6, and 8 g/d dose levels and with placebo.
RESULTS: Serum aminotransferase activities did not exceed the upper limit of the reference range (ULRR), except for one subject with an AST of 43 U/L (ULRR, 42 U/L), which was not considered clinically significant. All doses were generally well tolerated.
CONCLUSIONS: In a multiple-dose pharmacokinetics study of 4, 6, and 8 g/d of acetaminophen for 3 days, multiple aminotransferase determinations demonstrated no clinically important elevations at 1, 1.5, or 2 times the maximum recommended acetaminophen dose.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17357380     DOI: 10.1080/15563650601120792

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  5 in total

Review 1.  Pain management in the cirrhotic patient: the clinical challenge.

Authors:  Natasha Chandok; Kymberly D S Watt
Journal:  Mayo Clin Proc       Date:  2010-03-31       Impact factor: 7.616

Review 2.  Paracetamol for low back pain.

Authors:  Bruno T Saragiotto; Gustavo C Machado; Manuela L Ferreira; Marina B Pinheiro; Christina Abdel Shaheed; Christopher G Maher
Journal:  Cochrane Database Syst Rev       Date:  2016-06-07

3.  FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?

Authors:  Garry G Graham; Richard O Day; Andis Graudins; Anthoulla Mohamudally
Journal:  Inflammopharmacology       Date:  2010-03-07       Impact factor: 4.473

4.  Population Pharmacokinetic Modeling of Acetaminophen Protein Adducts in Adults and Children.

Authors:  Sibo Jiang; Kumpal Madrasi; Tanay Samant; Chakradhar Lagishetty; Valvanera Vozmediano; Angela Chiew; Susan M Abdel-Rahman; Laura P James; Stephan Schmidt
Journal:  J Clin Pharmacol       Date:  2019-12-04       Impact factor: 2.860

5.  Acetaminophen Protein Adducts in Hospitalized Children Receiving Multiple Doses of Acetaminophen.

Authors:  Sibo Jiang; Valvanera Vozmediano; Susan M Abdel-Rahman; Stephan Schmidt; Laura P James
Journal:  J Clin Pharmacol       Date:  2019-05-17       Impact factor: 3.126

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.